GE Healthcare Marks Ten Years Of Vivid Innovation
The acquisition of Vingmed Corp., Norway, in 1998 launched an unthinkable journey for GE Healthcare. At this year's meeting of the American Society of Echocardiography, in Toronto, GE Healthcare is commemorating the first ten years of that journey and celebrating the promise of the many tomorrows ahead.
Results Published Of ACCORD Clinical Trial
Intensively targeting blood sugar to near-normal levels in adults with type 2 diabetes at especially high risk for heart attack and stroke does not significantly reduce the risk of major cardiovascular events, such as fatal or nonfatal heart attacks or stroke, but increases risk of death, compared to standard treatment.
Carotid Artery Stenting Has Higher Risks Than Carotid Endarterectomy
A new study, will be presented at the Vascular Annual Meeting on June 5, 2008 that compares discharge data from patients who had carotid artery stenting (CAS) or carotid endarterectomy (CEA) in 2005. Researchers from the University of Massachusetts Medical School in Worcester, Mass.
Mesoblast Limited ASX:MSB Announce United States FDA Clears Phase 2 Trial For Congestive Heart Failure
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(USOTC:MBLTY)(PINK:MEOBF), announced that the United States Food and Drug Administration (US FDA) had cleared an Investigational New Drug (IND) submission by its US-based sister company, Angioblast Systems Inc.
Choosing The Right Type Of Stent For Your Clogged Coronary Artery
When they were introduced in 2003, drug-coated stents were hailed as a revolutionary new step in angioplasty, a surgical procedure to open a blocked coronary artery. But reports of heart attacks and deaths in a small number of patients soon forced a more careful examination of the risks of these devices.
Regado Biosciences Announces Publication In Circulation Of Clinical Trial Results Of REG1 Anticoagulation System
Regado Biosciences announced the journal Circulation has published clinical data from the Company's REG1 anticoagulation system Phase 1b dose-escalation study. REG1 is a two-component system comprised of an aptamer-based anticoagulant, RB006, and its matched antidote, RB007, which binds to and neutralizes RB006.
Endovascular Repair Of Aneurysms Reduces Mortality
Despite improvements in perioperative diagnosis, treatment and postoperative care, surgical repair of ruptured thoracic aortic aneurysms (r-TAA) has continued to have a high morbidity and mortality.However, a new study of endovascular repair of r-TAA was associated with markedly reduced mortality and improved mid-term survival, when compared to open surgical approach in a prospective intent-to-treat longitudinal study by the Albany Vascular Group in Albany, N.
Infrainguinal Bypass Surgery: High Perioperative Morbidity
A number of clinical and anatomic factors influence the decision between infrainguinal bypass surgeries (BPG) and endovascular procedures used to treat lower extremity vascular disease, according to a new database and early outcomes study presented at the Vascular Annual Meeting, June 5-8, in San Diego, Calif.
Latin American Women Are At Greater Risk Of Suffering Cardiovascular And Metabolic Diseases
A Spanish research study analysed the nutritional status and menstrual characteristics in a sample of native and immigrant Latin American girls. The data showed that immigrant girls have a higher percentage of body fat when they reach reproductive maturity which can be related to suffering cardiovascular and metabolic diseases.
Positive Clinical Data Evaluating The Micrus Endovascular Cerecyte Microcoil Published In Peer-Reviewed Journals
Micrus Endovascular Corporation (Nasdaq: MEND) today announced that positive data from two clinical studies evaluating the use of the Micrus Endovascular Cerecyte bioactive microcoil in the treatment of cerebral aneurysms have been published in peer-reviewed scientific journals.